10791

New strategies to Improve Success Rates of T and NK Cell-Mediated Cancer Immunotherapies

Baniyash Michal, HUJI, School of Medicine - IMRIC, Immunology and Cancer Research

Background

  • Novel T cell and NK cell based immunotherapeutic strategies are emerging as cancer treatments.  The success rate of these strategies is limited and depends on the type of cancer and the generated environment, with high recurrence rates.
  • The tumor generates inflammatory micro and macro environments leading to T and NK cell dysfunction.
  • There is an urgent need to protect the immune cells (T and NK cells) from the tumor generated host’s harmful environment and to enable their optimal anti-tumor function.

Our Innovation

  • Proprietary Cell-Induced Protection Strategy (CIPS) for T and NK cells using a unique protection molecule; Protection occurs within these cells and results in their resistance to the tumor induced harmful/immunosuppressive environment. Protection is achieved through a simple and reliable manipulation of the cells used for immunotherapy.
  • A single modification can protect the effector cells in 3 different types of immunotherapy: Lymphocytes in TIL (Tumor infiltrating lymphocytes), T Cells in TCR (Engineered T cell receptor) and NK cells (NK cell therapy).

 Opportunity

  • Counteract immunosuppression of adoptively transferred cells without a vast array of negative side effects.
  • Focus on the adoptively transferred cells instead of the multifactorial immunosuppressive environment.
  • Versatile integration of the protecting molecule to most/all existing and future vectors.
  • Broad utilization for various treatments utilizing both T and NK cells.
  • Potential impact of this concept for CAR therapy.
  • Novel approach based on a profound understanding of the mechanisms which cause an immune system to decrease activity as result of chronic inflammatory conditions caused by a variety of tumors

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
+972-2-6586692
Contact ME: